These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25316307)

  • 21. Changes in striatal activity and functional connectivity in a mouse model of Huntington's disease.
    Cabanas M; Bassil F; Mons N; Garret M; Cho YH
    PLoS One; 2017; 12(9):e0184580. PubMed ID: 28934250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum.
    Vetter JM; Jehle T; Heinemeyer J; Franz P; Behrens PF; Jackisch R; Landwehrmeyer GB; Feuerstein TJ
    J Neurochem; 2003 May; 85(4):1054-63. PubMed ID: 12716437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethological endophenotypes are altered by elevated stress hormone levels in both Huntington's disease and wildtype mice.
    Mo C; Renoir T; Hannan AJ
    Behav Brain Res; 2014 Nov; 274():118-27. PubMed ID: 25101541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
    Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
    Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
    Kraft JC; Osterhaus GL; Ortiz AN; Garris PA; Johnson MA
    Neuroscience; 2009 Jul; 161(3):940-9. PubMed ID: 19362126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.
    Hannan AJ; Ransome MI
    J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease.
    Pang TY; Du X; Zajac MS; Howard ML; Hannan AJ
    Hum Mol Genet; 2009 Feb; 18(4):753-66. PubMed ID: 19008301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resolving pathobiological mechanisms relating to Huntington disease: gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells.
    Kim HA; Jiang L; Madsen H; Parish CL; Massalas J; Smardencas A; O'Leary C; Gantois I; O'Tuathaigh C; Waddington JL; Ehrlich ME; Lawrence AJ; Drago J
    Neurobiol Dis; 2014 Feb; 62():323-37. PubMed ID: 24135007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
    Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
    Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
    Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
    Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice.
    Mo C; Pang TY; Ransome MI; Hill RA; Renoir T; Hannan AJ
    Neurobiol Dis; 2014 Sep; 69():248-62. PubMed ID: 24825316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.
    Petersén A; Puschban Z; Lotharius J; NicNiocaill B; Wiekop P; O'Connor WT; Brundin P
    Neurobiol Dis; 2002 Oct; 11(1):134-46. PubMed ID: 12460553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
    Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
    Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease.
    Cummings DM; Milnerwood AJ; Dallérac GM; Waights V; Brown JY; Vatsavayai SC; Hirst MC; Murphy KP
    Hum Mol Genet; 2006 Oct; 15(19):2856-68. PubMed ID: 16905556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.